BioCentury | Feb 1, 2020
Company News

Any chance left for safer opioids?

...Risk Management adcomms shot down oxycodegol (NKTR-181) from Nektar Therapeutics (NASDAQ:NKTR) and Aximiris XR from Intellipharmaceutics International Inc....
...product can be expected to deter abuse.” Lauren Martz, Senior Editor NKTR-181 U.S. Food and Drug Administration (FDA) Nektar Therapeutics Intellipharmaceutics International Inc. Opioid...
BioCentury | Jan 14, 2020
Company News

Amid need for new pain options, FDA panel rebuffs Nektar’s ‘safer’ opioid

...of tramadol and celecoxib from Esteve S.A. and an extended-release oral formulation of oxycodone from Intellipharmaceutics International Inc....
BioCentury | Sep 4, 2019
Company News

Sept. 4 Company Quick Takes: Boehringer licenses Lupin MEK inhibitor; plus BMS-BioMotiv, KemPharm-GPC, Lilly, Nektar and Intellipharmaceutics

...due to the postponement of FDA advisory committee meetings for opioid analgesics. Oxycodone ER from Intellipharmaceutics International Inc....
...Brand), LY2439821 (Compound #), ixekizumab (Generic), Taltz (Other) BioMotiv LLC Boehringer Ingelheim GmbH Bristol-Myers Squibb Co. Eli Lilly and Co. Intellipharmaceutics International Inc. KemPharm...
BioCentury | Oct 20, 2017
Clinical News

Intellipharmaceutics receives CRL from FDA for oxycodone ER

...In September, Intellipharmaceutics International Inc. (TSX:IPCI; NASDAQ:IPCI) received a complete response letter from FDA for an NDA for...
...for an NDA for oxycodone ER, a controlled-release formulation of oral oxycodone, to treat pain. Intellipharmaceutics...
...request additional time. Intellipharmaceutics International Inc. (TSX:IPCI; NASDAQ:IPCI), Toronto, Ontario Product: Oxycodone ER Business: Neurology Jennie Walters Rexista oxycodone XR Intellipharmaceutics International Inc. Opioid...
BioCentury | Sep 14, 2017
Company News

Management tracks: SymCel, Taro, Akcea

...Noor was CMO at Rugen Therapeutics Co. Ltd. (Jiangsu, China). Drug delivery and neurology company Intellipharmaceutics International Inc....
...for a principal financial officer. Jennie Walters Aeterna Zentaris Inc. Akcea Therapeutics Inc. Artios Pharma Ltd. AstraZeneca plc Biogen Inc. BioLamina AB Eyevensys S.A.S. Intellipharmaceutics International Inc. Kane...
BioCentury | Aug 11, 2017
Company News

Management tracks: Orchard, Maverick, Pieris

...He was a portfolio manager at Lombard Odier Asset Management (Geneva, Switzerland). Drug delivery company Intellipharmaceutics International Inc....
BioCentury | Jul 28, 2017
Clinical News

Panel rejects Intellipharmaceutics' Rexista abuse deterrence claims

...Safety & Risk Management Advisory Committees voted 22-1 against approval of Rexista oxycodone XR from Intellipharmaceutics International Inc....
...options are inadequate. Rexista’s PDUFA date is Sept. 25. The committee also voted 19-4 that Intellipharmaceutics...
...oral oxycodone. Intellipharmaceutics International Inc. (TSX:IPCI; NASDAQ:IPCI), Toronto, Ontario Product: Rexista oxycodone XR Business: Neurology Alicia Parker Rexista oxycodone XR Intellipharmaceutics International Inc....
BioCentury | Jul 27, 2017
Company News

Panel rejects Rexista abuse deterrence claims

...Safety & Risk Management Advisory Committees voted 22-1 against approval of Rexista oxycodone XR from Intellipharmaceutics International Inc....
...options are inadequate. Rexista’s PDUFA date is Sept. 25. The committee also voted 19-4 that Intellipharmaceutics...
...noted that there were no human abuse potential studies of Rexista. In 2015, FDA told Intellipharmaceutics...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

...OTCQX:IGXT) / RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) Rizaport rizatriptan Acute migraine Resubmit NDA 3Q17 Intellipharmaceutics International Inc....
BioCentury | Jul 5, 2017
Clinical News

FDA Panel to review Rexista NDA from Intellipharmaceutics

...Its PDUFA date is Sept. 25. The therapy is a controlled-release formulation of oral oxycodone. Intellipharmaceutics...
...the indication. Intellipharmaceutics International Inc. (TSX:IPCI; NASDAQ:IPCI), Toronto, Ontario Product: Rexista oxycodone XR Business: Neurology Julian Zhu Rexista Oxycodone XR Intellipharmaceutics International Inc. Opioid...
Items per page:
1 - 10 of 47
BioCentury | Feb 1, 2020
Company News

Any chance left for safer opioids?

...Risk Management adcomms shot down oxycodegol (NKTR-181) from Nektar Therapeutics (NASDAQ:NKTR) and Aximiris XR from Intellipharmaceutics International Inc....
...product can be expected to deter abuse.” Lauren Martz, Senior Editor NKTR-181 U.S. Food and Drug Administration (FDA) Nektar Therapeutics Intellipharmaceutics International Inc. Opioid...
BioCentury | Jan 14, 2020
Company News

Amid need for new pain options, FDA panel rebuffs Nektar’s ‘safer’ opioid

...of tramadol and celecoxib from Esteve S.A. and an extended-release oral formulation of oxycodone from Intellipharmaceutics International Inc....
BioCentury | Sep 4, 2019
Company News

Sept. 4 Company Quick Takes: Boehringer licenses Lupin MEK inhibitor; plus BMS-BioMotiv, KemPharm-GPC, Lilly, Nektar and Intellipharmaceutics

...due to the postponement of FDA advisory committee meetings for opioid analgesics. Oxycodone ER from Intellipharmaceutics International Inc....
...Brand), LY2439821 (Compound #), ixekizumab (Generic), Taltz (Other) BioMotiv LLC Boehringer Ingelheim GmbH Bristol-Myers Squibb Co. Eli Lilly and Co. Intellipharmaceutics International Inc. KemPharm...
BioCentury | Oct 20, 2017
Clinical News

Intellipharmaceutics receives CRL from FDA for oxycodone ER

...In September, Intellipharmaceutics International Inc. (TSX:IPCI; NASDAQ:IPCI) received a complete response letter from FDA for an NDA for...
...for an NDA for oxycodone ER, a controlled-release formulation of oral oxycodone, to treat pain. Intellipharmaceutics...
...request additional time. Intellipharmaceutics International Inc. (TSX:IPCI; NASDAQ:IPCI), Toronto, Ontario Product: Oxycodone ER Business: Neurology Jennie Walters Rexista oxycodone XR Intellipharmaceutics International Inc. Opioid...
BioCentury | Sep 14, 2017
Company News

Management tracks: SymCel, Taro, Akcea

...Noor was CMO at Rugen Therapeutics Co. Ltd. (Jiangsu, China). Drug delivery and neurology company Intellipharmaceutics International Inc....
...for a principal financial officer. Jennie Walters Aeterna Zentaris Inc. Akcea Therapeutics Inc. Artios Pharma Ltd. AstraZeneca plc Biogen Inc. BioLamina AB Eyevensys S.A.S. Intellipharmaceutics International Inc. Kane...
BioCentury | Aug 11, 2017
Company News

Management tracks: Orchard, Maverick, Pieris

...He was a portfolio manager at Lombard Odier Asset Management (Geneva, Switzerland). Drug delivery company Intellipharmaceutics International Inc....
BioCentury | Jul 28, 2017
Clinical News

Panel rejects Intellipharmaceutics' Rexista abuse deterrence claims

...Safety & Risk Management Advisory Committees voted 22-1 against approval of Rexista oxycodone XR from Intellipharmaceutics International Inc....
...options are inadequate. Rexista’s PDUFA date is Sept. 25. The committee also voted 19-4 that Intellipharmaceutics...
...oral oxycodone. Intellipharmaceutics International Inc. (TSX:IPCI; NASDAQ:IPCI), Toronto, Ontario Product: Rexista oxycodone XR Business: Neurology Alicia Parker Rexista oxycodone XR Intellipharmaceutics International Inc....
BioCentury | Jul 27, 2017
Company News

Panel rejects Rexista abuse deterrence claims

...Safety & Risk Management Advisory Committees voted 22-1 against approval of Rexista oxycodone XR from Intellipharmaceutics International Inc....
...options are inadequate. Rexista’s PDUFA date is Sept. 25. The committee also voted 19-4 that Intellipharmaceutics...
...noted that there were no human abuse potential studies of Rexista. In 2015, FDA told Intellipharmaceutics...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

...OTCQX:IGXT) / RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) Rizaport rizatriptan Acute migraine Resubmit NDA 3Q17 Intellipharmaceutics International Inc....
BioCentury | Jul 5, 2017
Clinical News

FDA Panel to review Rexista NDA from Intellipharmaceutics

...Its PDUFA date is Sept. 25. The therapy is a controlled-release formulation of oral oxycodone. Intellipharmaceutics...
...the indication. Intellipharmaceutics International Inc. (TSX:IPCI; NASDAQ:IPCI), Toronto, Ontario Product: Rexista oxycodone XR Business: Neurology Julian Zhu Rexista Oxycodone XR Intellipharmaceutics International Inc. Opioid...
Items per page:
1 - 10 of 47